New clinical trial testing diabetes drug for reducing risk of Alzheimer’s

pharmafile | December 13, 2021 | News story | Sales and Marketing  

A new study run by the Diabetes Trials Unit, and the Department of Psychiatry at the University of Oxford, alongside the global healthcare company Novo Nordisk, will examine whether semaglutide can prevent Alzheimer’s dementia at the earliest stage of brain change for those at risk of the disease.

Semaglutide, an orally administered diabetes medication, may be able to alter the course of the first changes that occur in the brain of those at risk of developing Alzheimer’s. The trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in Oxford, Imperial College London, University College London, Exeter, and Bristol. Participants with receive a Positron Emission Tomography (PET) head scan, examining levels of amyloid protein in their brains. It is believed that higher levels of this protein are linked to a higher risk of dementia.

The study participates to the growing field of research which tests the extended preclinical stage of dementia. This 10- to 20-year period during which the condition develops, but in which people do not have symptoms, is potentially an opportunity to interfere with the disease process, delaying or even preventing dementia.

“Developing an effective disease modifying therapy for Alzheimer’s disease remains one of the key unmet needs of modern medicine, given the increasing numbers of people developing this condition and the associated disability, societal costs, and reduced life expectancy,” shared Emeritus Professor Rury Holman, co-chair of the Trial Steering Committee, Diabetes Trials Unit, OCDEM, University of Oxford. “ISAP is another great example of academia and industry working together for the benefit of patients.”

Ana Ovey

Related Content

No items found

Latest content